PUR.WAR Pure Biologics Spólka Akcyjna
- Market cap
- PLN 35.9M
- P/E
- -
- P/B
- 0.75x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is PUR.WAR undervalued?
Graham numberThe Graham number of Pure Biologics Spólka Akcyjna cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pure Biologics Spólka Akcyjna fundamental analysis
4 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets (-564.9%) is below the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (64.2%) is above the industry median (2.6%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.6x) is below the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Pure Biologics Spólka Akcyjna stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.
Full company profilePure Biologics Spólka Akcyjna financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pure Biologics Spólka Akcyjna annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.29M | 982K | 9.53M | 16.8M | 572K | 254K | 662K | 95.0K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.11M | 878K | 6.69M | 12.8M | 299K | -4.03M | -5.41M | -2.57M | -46.0K | -159K | -12.0K |
| Operating Income | -419K | -386K | -631K | -4.37M | -11.6M | -10.5M | -24.6M | -31.7M | -12.4M | -6.33M | -6.78M |
| EBITDA | -384K | -248K | -465K | -1.64M | -8.30M | -8.62M | -22.8M | -26.1M | -12.1M | -6.17M | -6.67M |
| Net Income | -433K | -413K | -689K | -4.70M | -12.1M | -13.1M | -26.4M | -35.7M | -19.4M | -9.82M | -8.98M |
| EPS | -0.37 | -0.35 | -0.59 | -3.09 | -7.32 | -5.88 | -12 | -11 | -5.58 | -1.99 | -0.78 |
| Balance Sheet | |||||||||||
| Total Assets | 952K | 1.33M | 6.58M | 21.8M | 18.9M | 47.2M | 33.0M | 22.7M | 2.34M | 4.94M | 1.59M |
| Total Liabilities | 640K | 1.12M | 4.36M | 14.6M | 21.8M | 7.70M | 14.7M | 20.8M | 15.5M | 19.1M | 18.0M |
| Shareholders' Equity | 312K | 210K | 2.22M | 7.21M | -2.89M | 39.5M | 18.3M | 1.89M | -13.1M | -14.1M | -16.4M |
| Cash & Short-term Investments | 220K | 267K | 196K | 13.9M | 8.96M | 32.9M | 7.18M | 3.61M | 313K | 10.0K | 1.02M |
| Total Debt | - | 155K | 93.8K | 5.37M | 5.01M | 3.11M | 2.86M | 12.9M | 14.1M | 16.0M | 14.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -710K | -2.85M | -2.49M | 5.33M | -1.35M | -24.0M | -17.4M | -23.3M | -10.8M | -6.28M | -12.7M |
| Capital Expenditure | 441K | 162K | 162K | 162K | 561K | 673K | 5.76M | 176K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.15M | -2.85M | -2.65M | 5.17M | -1.91M | -24.7M | -23.1M | -23.4M | -10.8M | -6.28M | -12.7M |
| Ratios | |||||||||||
| ROE | -138.9% | -196.7% | -31.0% | -65.2% | - | -33.1% | -144.1% | -1,885.6% | - | - | - |
| ROA | -45.5% | -31.1% | -10.5% | -21.6% | -63.9% | -27.7% | -79.9% | -157.0% | -829.5% | -198.8% | -564.9% |
| Net Profit Margin | -33.6% | -42.0% | -7.2% | -28.1% | -2,116.3% | -5,146.1% | -3,983.7% | -37,572.6% | - | - | - |
| Debt to Equity | - | 0.74x | 0.04x | 0.74x | - | 0.08x | 0.16x | 6.83x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pure Biologics Spólka Akcyjna dividends
Pure Biologics Spólka Akcyjna has not paid dividends in the last 9 fiscal years.
Last stock split: 1042:621 on Jul 11, 2025.
Who owns Pure Biologics Spólka Akcyjna
- Insiders 72.43%
- Institutions 18.63%
- Public & others 8.94%
- Shares outstanding 12.2M
- Free float 10.7M
Pure Biologics Spólka Akcyjna company profile
- Company name
- Pure Biologics Spólka Akcyjna
- Ticker
- PUR.WAR
- ISIN
- PLPRBLG00010
- Exchange
- Warsaw Stock Exchange
- Sector
- -
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- Szczytnicka 11, Wroclaw, Poland, 50-382
- Phone
- 48 57 000 2829
- Website
- purebiologics.com
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.
Pure Biologics Spólka Akcyjna management
4- Dr. Filip Jelen M.B.A., Ph.D.Co-founder & President of the Management Board
- Dr. Slawomir WojcikMember of Management Board
- Mr. Przemyslaw DudekHead of Information Technology
- Dr. Ewelina Swiderek Ph.D.Head of Project Management